Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXA-HAIC plus S-1 for advanced hepatocellular carcinoma with portal vein tumor thrombus
ChiCTR-OIC-16007966Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Xinjiang Medical University
- Start
- Mar 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and tegafur in hepatocellular carcinoma (HCC), sponsored by Affiliated Cancer Hospital of Xinjiang Medical University. Primary endpoints: Adverse reactions and Time to progression. Started Mar 2016; status: recruiting.
02
Drugs
oxaliplatintegafur
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-OIC-16007966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16007966.